Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 over exp PD173074 uterus leiomyosarcoma sensitive detail...
FGFR1 over exp AZD4547 uterus leiomyosarcoma sensitive detail...
FGFR1 over exp BGJ398 uterus leiomyosarcoma sensitive detail...
FGFR1 positive PD173074 uterus leiomyosarcoma decreased response detail...
FGFR1 positive AZD4547 uterus leiomyosarcoma decreased response detail...
FGFR1 positive BGJ398 uterus leiomyosarcoma decreased response detail...
Unknown unknown Pazopanib uterus leiomyosarcoma not applicable detail...
AKT1 E17K Capivasertib uterus leiomyosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02428192 Phase II Nivolumab Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma Completed
NCT02963831 Phase Ib/II ONCOS-102 + MEDI4736 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting